Abstract
Abstract: The coronavirus disease 19 (COVID-19) is a pandemic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, COVID-19 has affected 210 countries and territories around the world. But there is no clinically approved antiviral drug or vaccine against COVID-19. Governments, private manufactures, academic institutions and non-profit organizations are working hard at a breakneck pace to develop a vaccine for COVID-19. However, vaccine development is very lengthy and expensive process, typically takes many years to produce a licensed vaccine. Because of the high failure rates and cost factors, developers generally follow a linear development sequence with multiple pauses for analysis of data. But in view of the COVID-19 pandemic, development steps need to be executed parallel before confirming the outcome of the previous step. In the current review, we summarize the process involved in the COVID-19 vaccine development and its challenges. Key words: Candidate Vaccine, Corona Virus, COVID-19 Vaccine, SARS-CoV-2, Vaccine Clinical Trial, Vaccine Development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Indian Journal of Pharmaceutical Education and Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
